NewLimit

NewLimit has raised a $130B Series B led by @kleinerperkins with new investors @natfriedman/@danielgross, @khoslaventures, @humancapital & returning investors @_DimensionCap, @foundersfund We're grateful for their boldness in joining us on our journey to extend human healthspan

New Raise 🏛️ Company: NewLimit 🔗 Website: https://t.co/OVTliCR9iI 📊 Amount: $130 Million 🔄 Round: Series B 🧮 Valuation: N/A ⚙️ Industry: Biotechnology

🔔 Coinbase CEO Brian Armstrong’s longevity startup NewLimit just raised $130M in Series B funding at a $810M valuation. The goal? Reprogram human cells to slow aging and restore function — starting with the liver. Crypto built the rails. Now it’s funding the future of life

🚀 NewLimit Secures $130M to Advance Liver Reprogramming Therapy NewLimit, the anti-aging biotech co-founded by Coinbase CEO Brian Armstrong, has raised $130 million in a Series B funding round led by Kleiner Perkins. This investment aims to propel their mRNA-based liver https://t.co/X7RTdAzh6b

NewLimit has raised a $130 million Series B to advance epigenetic reprogramming research aimed at aging. Backed by Coinbase CEO Brian Armstrong, the startup says human trials are on the horizon. https://t.co/FzVTTzwjF2

🔔 @Coinbase Co-Founder’s Longevity Startup @NewLimit Raises $130M at $810M Valuation ! #Longevity startup #NewLimit, co-founded by #Coinbase’s @brian_armstrong, has raised $130 million in a Series B round led by Kleiner Perkins, valuing the company at $810 million, according to https://t.co/x29eHQ2iU0

NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, Blake Byers, and stem cell expert Jacob Kimmel, has raised $130 million in a Series B round led by Kleiner Perkins to advance its mission... https://t.co/u3cpXHNoYe

Just In ⚠️ Coinbase Co-Founder’s Startup NewLimit Raises $130M at $810M Valuation ! Longevity startup NewLimit, co-founded by Coinbase’s Brian Armstrong, has raised $130 million in a Series B round led by Kleiner Perkins, valuing the company at $810 million, according to https://t.co/Y1pbhNsoQV

Just In ⚠️ Coinbase Co-Founder’s Startup NewLimit Raises $130M at $810M Valuation ! Longevity startup NewLimit, co-founded by Coinbase’s Brian Armstrong, has raised $130 million in a Series B round led by Kleiner Perkins, valuing the company at $810 million, according to

.@newlimit, a longevity startup founded by @coinbase's @brian_armstrong, raised $130 million in a Series B round, valuing the company at $810 million Investor: @kleinerperkins, @khoslaventures, and @human_protocol. https://t.co/Xa2XoJNn2L https://t.co/BQgozTnMro

Big $130M series B funding round for New Limit, who are seeing milestone results faster than expected https://t.co/xk1U8NP6ME

Crypto Bros Are Grabbing Power Right now, the world is busy talking about the India-Pakistan war, but honestly, I really don’t want to focus on that. Brian Armstrong’s company, NewLimit — yes, it's Brian who’s the CEO of Coinbase — just raised $130 million in a Series B round. https://t.co/SbYjnKBDSx

$btc cofounder brian armstrong's biotech firm newlimit raised $130m in series b funding to combat aging with ai and genomics ​​​​‌​‌​‌‌ Follow coin captain for more AI alerts

$btc cofounder brian armstrong's biotech firm newlimit raised $130m in series b funding to combat aging with ai and genomics ​​​​‌​‌​‌‌

.@newlimit, which was cofounded by Coinbase CEO @brian_armstrong, is working to develop medicines that target drivers of aging using AI and epigenetics—and has raised $130 million in series B funding. https://t.co/YVdUROpwzh

🚀 Big news in the longevity game! NewLimit, co-founded by Coinbase's Brian Armstrong, just snagged a whopping $130 million in their Series B round, bringing their valuation to $810 million! 💰✨ Their mission? To turn back the clock on aging by reprogramming our genes and